Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine with High-Dose Idarubicin in Older AML
NCT00086099Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jul 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of amifostine in acute myeloid leukemia (AML), sponsored by MedImmune. Started Jul 2004; status: completed.
02
Drugs
amifostine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00086099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086099.